2025 Key Updates in Science and Policy

Picture of Patrick Wang

Patrick Wang

Expert of Peptides | Ask me anything about Peptides | Sales Manager at AHB Lab
Cover

Table of Contents

From recent advances to challenges and ethical dilemmas that shape the scientific landscape, this article encompasses it all-from the intersection of science and policy. We cover all aspects, from AlphaFold3’s release of revolutionary AI code and the disturbing reproducibility crisis in biomedical research to the lapses in financial conflict disclosures and changes in public health and environmental policies. In addition, we discuss how research chimpanzees are being moved to sanctuaries and also a rather exciting cosmic find dealing with galaxies coming in pairs. Taken altogether, each of these news items provides quite the broad vision of challenging interactions among innovation, regulation, and society.

 

AlphaFold3 Code Released: A Breakthrough for Protein Prediction

In a long-awaited move, Google DeepMind just released the code for its super-advanced artificial intelligence software called AlphaFold3. Immediately, excitement erupted across the research community. AlphaFold3 was announced in Nature on May 8 for being able to predict protein structures and interactions with DNA, RNA, and other proteins in a way no other program has ever done-a major advance toward drug discovery and other scientific uses.

But that code was finally released more than six months after the presentation, to the frustration of many researchers. Critics said at that time that a lack of immediate access impeded reproducibility with only pseudocode and limited-use online portal available at that time. Now, on November 11, DeepMind released the complete code and model weights for non-commercial uses to allow the researchers to replicate the findings and build on them. The company also emphasized that at least a few groups had already reproduced AlphaFold3 from the pseudocode, itself demonstrating the reproducibility of the Nature paper.

 

Biomedical Studies Face Reproducibility Crisis

A recent global survey of biomedical research has exposed a disturbing trend: replication failures. Published in PLOS Biology, the survey of 1,630 biomedical scientists included 880 who said they had attempted to replicate another researcher’s work. Shockingly, 724 of those attempts failed, and nearly one-fourth of respondents admitted they couldn’t reproduce their own experiments.

This survey underlines a wider problem: 72% of those responding to the survey agreed there was a reproducibility crisis in the field. Scientists said that intense pressure to publish along with a lack of institutional and funding support are key drivers of irreproducible studies into journals. These findings really echo a 2016 survey in Nature that reported similar concerns across multiple scientific disciplines.

 

Financial Conflicts in Research Often Go Unflagged

A new study has exposed a surprising gap in the way financial conflicts of interest are disclosed in life sciences research. Published in PLOS ONE, the analysis examined 3,888 articles from 40 high-impact journals published in 2021 and 2022. The surprise conclusion: only 30% of the articles disclosed potential conflicts of interest, and just half of those disclosures were flagged in the National Institutes of Health’s PubMed database.

Since 2017, PubMed has had a field for conflict-of-interest statements, in hopes of making those disclosures more transparent. But the study found that many journals don’t use the feature very well. In an expanded analysis including 7,000 journals, just one-third submitted conflict-of-interest statements to PubMed – a factor some scientists consider important to the transparency and accountability of science publishing.

 

Public Health Under Scrutiny: RFK Jr.’s Potential Impact

As Donald Trump gets to work, one of his first moves is to embolden a vaccine skeptic: Robert F. Kennedy Jr. The public health world goes into high alert. This is an environmental lawyer whose past proposals have included banning fluoride from public water supplies and dismantling key departments of the FDA. Lawrence Gostin, a specialist in public health law, describes this as “the darkest day for public health and science in my lifetime.”

While the FDA and CDC enjoy a degree of independence from federal agencies, Kennedy’s presence has the potential to blow vaccine policy off course and undermine confidence in public health measures. Public health systems operating at the state level might struggle to hang onto evidence-based vaccination mandates. Experts caution that this erosion of trust in public health guidance is going to continue, with the consequence of complicating efforts to address the pressing health challenges even further.

 

Trump’s EPA Pick: Deregulation on the Horizon

President-elect Trump made a choice to lead the EPA that elicited sharp reactions. Now he’s nominated Lee Zeldin, the former New York congressman, to helm the agency. Zeldin has been known for his deregulatory position and recently promised to “unleash American businesses” with environmental protection rollbacks.

Environmental watchdog groups sound the alarm, pointing to Zeldin’s abysmal environmental voting record as their prime argument while in Congress. His nomination presages a rule of weakened critical climate policies and increased political interference in research programs at the EPA, says an advisory group; such actions warn of far-reaching ramifications on environmental health and safety.

 

Chimps Relocated to Sanctuary After Longstanding Debate

The U.S. National Institutes of Health said it will relocate 23 retired research chimpanzees from a New Mexico facility to the Chimp Haven sanctuary in Louisiana. The move is in line with major steps toward ending invasive biomedical research on chimpanzees, which NIH officially declared over in 2015.

The decision comes after years of controversy. In 2019, NIH ruled too many chimps were too old or ill to move-a decision that generated outrage among animal welfare activists. Questions about staffing at the current facility ultimately proved the catalyst for the agency’s change of heart. Chimp Haven expects the first arrivals to begin in early 2025 and plans other transfers for research chimps.

 

Stroke Researcher Takes Leave Amid Misconduct Allegations

Prominent Alzheimer’s and stroke researcher Berislav Zlokovic has been put on indefinite leave from the University of Southern California amid allegations of research misconduct. A year-long Science investigation found in many quarters a broad-spectrum concern about work overseen by Zlokovic, which has already caused a $30 million clinical trial to be canceled for a stroke drug candidate he helped develop.

Furthermore, the case required USC to refund approximately $2 million in funding allocated for the trial from the U.S. National Institutes of Health. The case sheds light on how challenging it is yet to maintain integrity in research, especially in high-stakes research, such as biomedical research.

 

Cosmic Discovery: Dual Galaxies Create Compound Lens

Astronomers have caught a rare cosmic alignment-two lined-up galaxies commanding a compound gravitational lens. This peculiar configuration distorts and magnifies light coming from a distant quasar, a super-massive black hole spewing intense radiation.

In a new work, using NASA’s James Webb Space Telescope and many other instruments, they studied six sharp images of the quasar, magnified up to 40 times. The zigzag path the light takes around the galaxies marks out a new tool for measuring the rate of expansion and history of the universe. The results are yet to be peer-reviewed and have been released as a preprint on arXiv. The study could have far-reaching implications for cosmology and the nature of dark matter.

 

Conclusion

This eclectic mix of stories about scientific and policy developments underlines the opportunities and challenges that face both researchers and policymakers in this week’s news. Tales of artificial intelligence advances, juxtaposed with ethical dilemmas and public health, raise a number of questions with regard to innovation, regulation, and societal consequence.

At AHB Lab, we’re dedicated to keeping you updated on these pivotal developments and their implications for our industry. Stay connected for more insights!

Leave a Reply

Your email address will not be published. Required fields are marked *

公司最新訊息

你的消炎藥只是在「關掉煙霧探測器」?從源頭阻斷慢性發炎的胜肽科學

為什麼你的疲倦與疼痛總是反覆發作? 你是不是經常覺得關節痠痛、莫名疲倦,或者有各種過敏和腸胃問題,卻始終找不出確切原因 ? 在現代高壓與快節奏的生活中,許多人都在尋求這些亞健康狀態的解藥。事實上,現代人90%的慢性病,其實都來自同一個源頭:你體內有一把撲不滅的「無名火」,醫學上稱之為「慢性發炎」 。 當面臨這些不適,多數人的第一反應是服用非類固醇消炎藥(NSAIDs)或類固醇。然而,這些傳統藥物往往只能提供短暫的舒緩,一旦停藥,症狀便會捲土重來。這不禁讓我們反思:我們是否只在處理表面症狀,而忽略了真正的問題根源?   傳統消炎藥的盲點與機制 要理解傳統藥物的局限性,我們必須先了解發炎的運作機制。當身體受到外界刺激時,免疫系統中的「巨噬細胞」會釋放 TNF-α 和 IL-1β 等發炎細胞因子 。這本是身體為了防禦而響起的警報器,但當免疫系統失衡,這些發炎因子便會失控形成「細胞因子風暴」,開始無差別攻擊正常細胞、黏膜和關節,甚至破壞 DNA 。 傳統的西藥如 NSAIDs 是如何運作的呢?它們主要的作用機制是抑制下游的 COX-1 或 COX-2 酵素 。 為了讓大家更直觀地理解,我們可以比較一下這兩種機制的差異:

Read More
公司最新訊息

止痛藥的隱形代價:淨火肽如何透過「8小時降解」機制重塑無毒抗炎新標準?

引言 在現代高壓的生活節奏中,面對關節痠痛或慢性疲勞,多數人的第一反應往往是去藥房購買非類固醇消炎止痛藥,或是服用醫生開立的類固醇 。當藥效發揮,疼痛的警報聲停止,我們便誤以為身體恢復了健康 。 然而,你吞下的那顆止痛藥,在讓你感覺不到痛之後,究竟去了哪裡? 這是一個多數消費者忽略,而品牌研發端必須正視的痛點。傳統藥物在體內的作用機制,實際上只是粗暴地抑制了下游的 COX 酵素 。這就像是一群莽漢直接砸爛了火災警報器,卻對真正引發火災的源頭無能為力 。更嚴重的是,這些無法被身體完全辨識與利用的化學合成物,在完成掩蓋任務後並不會憑空消失,而是轉化為化學廢棄物 。 這些殘留物迫使肝臟超負荷運作以進行代謝,同時也讓腎臟拼命處理排毒 。由於 COX 酵素被過度抑制,人體保護胃壁的機制隨之停擺,最終導致腸胃黏膜逐漸受到破壞 。這不是真正的治療,而是一場用內臟健康換取短暫不痛的恐怖交易 。身為保健或保養品牌的決策者,我們必須思考:除了這種「拆東牆補西牆」的化學療法,我們能否為市場提供一種更安全、無毒的解答?   核心機制深潛 為了解決傳統消炎藥物的瓶頸,富比積生物科技(AHB Lab)突破傳統藥理學限制,研發出名為「淨火肽 Healtide®」的第三代生物合成定序胜肽 。這項技術透過「生物黑客」的思維,重新定義了抗炎機制的標準。   1.

Read More
公司最新訊息

你體內的「無名火」正在搞破壞!一招從源頭撲滅慢性發炎(淨火肽 Healtide® 機理大解密)

為什麼吃了消炎藥,身體的「火」還是滅不掉? 你是否經常遇到這樣的客戶反饋:消費者面對關節痠痛、過敏、腸胃不適或皮膚慢性暗沉,長期服用非類固醇消炎藥(NSAIDs)或塗抹類固醇,卻總是反覆發作、治標不治本 ?   現代醫學與功能生物學證實:90% 的慢性疾病與老化瓶頸,核心源頭都來自體內撲不滅的「慢性發炎」。 傳統生技產品或化學藥物的開發邏輯,大多著眼於抑制下游的 COX-1 或 COX-2 酵素 。用一個心智模型(Mental Model)來比喻:這就像火災發生時,你只是跑去「關掉煙霧探測器」,卻根本沒有沒收那個正在不斷點火的「打火機」! 長期下來,不僅無法根除發炎,化學藥物更可能增加肝腎與腸胃道的代謝負擔 。 市場正在尋找一種更高訊噪比、能「從源頭斷火」且安全無副作用的革命性生物素材。這正是富比積生物科技(AHB Lab)董事長莊國昇博士與研發團隊,成功推出第三代生物合成定序胜肽——淨火肽(Healtide®)的契機 。   淨火肽(Healtide®)的源頭阻斷機制 當人體受到刺激時,免疫系統的「巨噬細胞」會釋放 TNF-α(腫瘤壞死因子)與 IL-1β 等發炎細胞因子 。一旦失控,就會引發無差別攻擊正常組織的「細胞因子風暴」

Read More